Clinical Trial: A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760519) titled 'A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC' on June 17.

Brief Summary: This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.

Study Start Date: Sept. 30

Study Type: OBSERVATIONAL

Condition: Carcinoma, Non-Small-Cell Lung

Intervention: OTHER: IMFINZI

IMFINZI

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AstraZeneca

Published by HT Digital Content Services with permission from Health Daily Digest....